Search Results - "Iaffaioli, V. R."

Low doses of Bisphenol A have pro-inflammatory and pro-oxidant effects, stimulate lipid peroxidation and increase the cardiotoxicity of Doxorubicin in cardiomyoblasts by Quagliariello, V., Coppola, C., Mita, D.G., Piscopo, G., Iaffaioli, R.V., Botti, G., Maurea, N.

“…[Display omitted] •Bisphenol A increase the Doxorubicin-Induced cardiotoxicity.•Bisphenol A have pro-oxidative and pro-inflammatory effects in…”
Get full text

Cross-linked hyaluronic acid sub-micron particles: in vitro and in vivo biodistribution study in cancer xenograft model by Rosso, F., Quagliariello, V., Tortora, C., Di Lazzaro, A., Barbarisi, A., Iaffaioli, R. V.

“…This paper focused on the biodistribution of the cross-linked hyaluronic acid (HA-NPs) sub-micron particles in tumor-bearing mice. Solvent-non solvent method…”
Get full text

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma by De Divitiis, C, von Arx, C, Grimaldi, A M, Cicala, D, Tatangelo, F, Arcella, A, Romano, G M, Simeone, E, Iaffaioli, R V, Ascierto, P A, Tafuto, S

“…Neuroendocrine Neoplasms (NEN) are a group of heterogeneous malignancies derived from neuroendocrine cell compartment, with different roles in both endocrine…”
Get full text

Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials by Nasti, G, Ottaiano, A, Berretta, M, Delrio, P, Izzo, F, Cassata, A, Romano, C, Facchini, G, Scala, D, Mastro, A, Romano, G, Perri, F, Iaffaioli, R. V

“…The standard treatment of CRC patients with hepatic metastases is systemic chemotherapy; however, 5-year survival is disappointingly poor despite recent…”
Get full text

Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer by DI MAIO, M, GRIDELLI, C, FRONTINI, L, ROSETTI, F, CARROZZA, F, BEARZ, A, SPATAFORA, M, ADAMO, V, ISA, L, LAFFAIOLI, R. V, DI SALVO, E, PERRONE, F, GALLO, C, MANZIONE, L, BRANCACCIO, L, BARBERA, S, ROBBIATI, S. F, LANNIELLO, G. P, FERRAU, F, PIAZZA, E

“…Pain is a highly distressing symptom for patients with advanced cancer. WHO analgesic ladder is widely accepted as a guideline for its treatment. Our aim was…”
Get full text

Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab by Quagliariello, V., Passariello, M., Coppola, C., Rea, D., Barbieri, A., Scherillo, M., Monti, M.G., Iaffaioli, R.V., De Laurentiis, M., Ascierto, P.A., Botti, G., De Lorenzo, C., Maurea, N.

“…The immunotherapy has revolutionized the world of oncology in the last decades with considerable advantages in terms of overall survival in cancer patients…”
Get full text

Ozone Exerts Cytoprotective and Anti-Inflammatory Effects in Cardiomyocytes and Skin Fibroblasts after Incubation with Doxorubicin by Maurea, N., Iaffaioli, R. V., Franzini, M., Quagliariello, V., Simonetti, V., Valdenassi, L.

“…Introduction. Skin reactions and cardiotoxicity are one of the most common side effects of doxorubicin in cancer patients. The main mechanisms based on the…”
Get full text

Therapy of metastatic bladder carcinoma by Iaffaioli, RV, Milano, A, Caponigro, F

“…The methotrexate, vinblastine, doxorubicin, cisplatin (M-VAC) regimen has been considered as standard treatment of metastatic bladder carcinoma till recent…”
Get full text

SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications? by Quagliariello, V, Bonelli, A, Caronna, A, Lombari, M C, Conforti, G, Libutti, M, Iaffaioli, R V, Berretta, M, Botti, G, Maurea, N

“…NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we…”
Get more information

An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer by Tambaro, R., Greggi, S., Iaffaioli, R. V., Rossi, A., Pisano, C., Manzione, L., Ferrari, E., Di Maio, M., Iodice, F., Casella, G., Laurelli, G., Pignata, S.

“…Background: The aim of this study was to determine the maximum tolerated dose (MTD) of liposomal doxorubicin (LD)–vinorelbine (V) in patients with refractory…”
Get full text

Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial by Nasti, G, Piccirillo, M C, Izzo, F, Ottaiano, A, Albino, V, Delrio, P, Romano, C, Giordano, P, Lastoria, S, Caracò, C, de Lutio di Castelguidone, E, Palaia, R, Daniele, G, Aloj, L, Romano, G, Iaffaioli, R V

“…Background: Preoperative treatment of resectable liver metastases from colorectal cancer (CRC) is a matter of debate. The aim of this study was to assess the…”
Get full text

A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology by Ottaiano, A, Budillon, A, Normanno, N, Iaffaioli, VR, Caraglia, M

Get full text

Small tumor of the medial breast presenting with a contralateral lymph node involvement detected on positron emission tomography scan by Facchini, G, Caraglia, M, Nasti, G, Ottaiano, A, Franco, R, La Mura, A, Fulciniti, F, Libutti, M, Ruberto, M, Marra, M, Budillon, A, Iaffaioli, RV

Get full text

Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial by Gridelli, Cesare, Perrone, Francesco, Gallo, Ciro, Cigolari, Silvio, Rossi, Antonio, Piantedosi, Francovito, Barbera, Santi, Ferraù, Francesco, Piazza, Elena, Rosetti, Francesco, Clerici, Maurizia, Bertetto, Oscar, Robbiati, Sergio Federico, Frontini, Luciano, Sacco, Cosimo, Castiglione, Federico, Favaretto, Adolfo, Novello, Silvia, Migliorino, Maria Rita, Gasparini, Giampietro, Galetta, Domenico, Iaffaioli, Rosario Vincenzo, Gebbia, Vittorio

“…Background: Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC). Some studies have…”
Get full text

Expression of CD40 has no predictive value in soft tissue sarcomas by Ottaiano, A, Pisano, C, De Chiara, A, Barletta, E, Ascierto, A P, Botti, G, Napolitano, M, Apice, G, Iaffaioli, R V

“…CD40, a member of the tumor necrosis factor receptor superfamily, is capable of mediating the induction of apoptosis in tumors including sarcomas. The…”
Get more information

Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers by Strocchi, E, Iaffaioli, R.V, Facchini, G, Mantovani, G, Ricci, S, Cavallo, G, Tortoriello, A, D'Angelo, R, Formato, R, Rosato, G, Fiore, F, Iaccarino, V, Petrella, G, Memoli, B, Santangelo, M, Camaggi, C.M

“…Aim. To verify the rationale of a pelvic stop-flow technique for the perfusion of high-doses of mitomycin C and anthacyclines in patients with inoperable,…”
Get full text

A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications by Facchini, G., Fiore, F., Caraglia, M., D'Angelo, R., Nasti, G., Caponigro, F., Formato, R., Budillon, A., Iaffaioli, R. V.

Get full text

Intermittent chemotherapy in advanced colorectal cancer: is it the future? by Ottaiano, A., Di Lazzaro, A., Iaffaioli, V. R.

Get full text

Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas: five-year results with epirubicin and ifosfamide by Ottaiano, A, De Chiara, A, Fazioli, F, De Rosa, V, Ravo, V, Boccia, V, Botti, G, Petrillo, A, Fiore, F, Mori, S, Mozzillo, N, Iaffaioli, V R, Apice, G

“…Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas (STS) may provide some advantages for facilitating the surgical resection of the…”
Get more information

A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer by IAFFAIOLI, R. V, TORTORIELLO, A, ANTONELLI, B, VALLEFUOCO, V, MOSELLA, G, CAPONIGRO, F, FACCHINI, G, SANTANGELO, M, DE SENA, G, GESUE', G, BUCCI, L, SCARAMELLINO, G, ANASTASIO, E, FINIZIO, A

“…Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95%…”
Get full text